Gain Therapeutics Q2 2026 net loss $0.11/share; FDA clears IND for rexaceract Phase 2

Gain Therapeutics, Inc.

Net loss per share $0.11 (basic/diluted) vs $0.19 in Q2 2025; cash $13.1M at June 30, 2026.
FDA accepted IND for rexaceract (GT-02287); Phase 2 in Parkinson's expected to start Q3 2026.
R&D expenses fell to $2.1M from $2.8M; G&A rose to $2.5M from $2.3M year-over-year.
Phase 1b final results due Q4 2026; 14 of 16 extension participants completed Day 270.
Promoted Joanne Taylor to CSO and Terenzio Ignoni to COO; GT-04686 indication expected by year end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.